
    <!DOCTYPE html>
    <html lang="zh-CN">
    <head>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <title>Yong Wang, Yanan Wang, Lei Bao et al.. Nature communications. 2025.</title>
        <style>
            body {
                font-family: Arial, sans-serif;
                line-height: 1.6;
                max-width: 800px;
                margin: 0 auto;
                padding: 20px;
                color: #333;
            }
            h1 {
                color: #2c3e50;
                border-bottom: 1px solid #eee;
                padding-bottom: 10px;
            }
            .authors {
                font-weight: bold;
                margin: 10px 0;
            }
            .journal {
                color: #7f8c8d;
                font-style: italic;
            }
            .abstract {
                background-color: #f9f9f9;
                padding: 15px;
                border-radius: 5px;
                margin: 15px 0;
            }
            .keywords {
                font-style: italic;
                color: #7f8c8d;
            }
            .doi-link {
                color: #27ae60;
                text-decoration: none;
            }
            .doi-link:hover {
                text-decoration: underline;
            }
            .back-link {
                display: inline-block;
                margin-top: 20px;
                padding: 5px 10px;
                background-color: #2980b9;
                color: white;
                text-decoration: none;
                border-radius: 3px;
            }
            .back-link:hover {
                background-color: #3498db;
            }
        </style>
    </head>
    <body>
        <h1>ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27.</h1>
        <div class="authors">Yong Wang, Yanan Wang, Lei Bao et al.</div>
        <div class="journal">Nature communications, Apr 2025</div>
        <div>
            PMID: 40281007
            | <a href="https://doi.org/10.1038/s41467-025-59184-5" class="doi-link" target="_blank">DOI链接</a>
        </div>
        
        <div class="abstract">
            <h3>摘要</h3>
            <p>Anti-HER2 antibodies are effective but often lead to resistance in patients with HER2+ breast cancer. Here, we report an epigenetic crosstalk with aberrant glycerophospholipid metabolism and inflammation as a key resistance mechanism of anti-HER2 therapies in HER2+ breast cancer. Histone reader ZMYND8 specifically confers resistance to cancer cells against trastuzumab and/or pertuzumab. Mechanistically, ZMYND8 enhances cPLA2α expression in resistant tumor cells through inducing c-Myc. cPLA2α inactivates phosphatidylcholine-specific phospholipase C to inhibit phosphatidylcholine breakdown into diacylglycerol, which diminishes protein kinase C activity leading to interleukin-27 secretion. Supplementation with interleukin-27 protein counteracts cPLA2α loss to reinforce trastuzumab resistance in HER2+ tumor cells and patient-derived organoids. Upregulation of ZMYND8, c-Myc, cPLA2α, and IL-27 is prevalent in HER2+ breast cancer patients following HER2-targeted therapies. Targeting c-Myc or cPLA2α effectively overcomes anti-HER2 therapy resistance in patient-derived xenografts. Collectively, this study uncovers a druggable signaling cascade that drives resistance to HER2-targeted therapies in HER2+ breast cancer.</p>
        </div>
        
        <div class="keywords">
            <strong>关键词:</strong> No keywords available
        </div>
        
        <a href="index.html" class="back-link">返回文献列表</a>
    </body>
    </html>
    